SBI-993 is a SBI-477 analog with improved potency and suitable pharmacokinetic properties for in vivo bioavailability. SBI-993 stimulates insulin signaling by deactivating the transcription factor MondoA[1].
SBI-993 reduces thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4) expression in human myotubes[1].
SBI-993 (50 mg/kg; s.c.; daily; for 7 days) treatment reduces the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver. SBI-993 also reduces Txnip and Arrdc4 expression. And ccupation of both ChREBP and MondoA on the Txnip and pyruvate kinase (Pklr) gene promoters is reduced in liver by SBI-993[1].
SBI-993 improves insulin signaling in both muscle and liver following an acute insulin challenge[1].
| Animal Model: | Mice are fed a 60% high-fat diet (HFD)[1] |
| Dosage: | 50 mg/kg |
| Administration: | s.c.; daily; for 7 days |
| Result: | Reduced the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver. |
[1]. Byungyong Ahn, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1;126(9):3567-79.